Full Text View
Tabular View
No Study Results Posted
Related Studies
Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Preserved)
This study has been completed.
Study NCT00634712   Information provided by AstraZeneca

First Received on March 7, 2008.   Last Updated on January 24, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Congestive Heart Failure
Additional conditions recognized in this trial
Heart Failure
More general conditions related to this trial
Cardiovascular Diseases
Heart Diseases
Interventions listed in this trial
Candesartan
Placebo
Additional drug interventions recognized in this trial
Candesartan cilexetil
More general drug interventions related to this trial
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Antihypertensive Agents
Cardiovascular Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
AstraZeneca


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services